TB-4 Frag

TB-4 Fragment represents a specific peptide sequence derived from the full-length thymosin beta-4 (Tβ4) molecule. Research has explored whether smaller fragments of Tβ4 retain the regenerative and healing properties of the parent peptide while offering advantages in synthesis, stability, or cost. Various TB-4 fragments have been studied, with some retaining actin-binding capabilities and wound-healing properties. The most commonly referenced fragment includes the actin-binding domain responsible for Tβ4's effects on cell migration and tissue repair. Studies examining fragments suggest some biological activity is preserved, though typically at reduced potency compared to full-length TB-500/Tβ4. The appeal of fragments lies in potentially lower cost and simpler synthesis while maintaining therapeutic relevance. However, research on TB-4 fragments is considerably more limited than on full-length thymosin beta-4, and the optimal fragment sequence for different applications remains under investigation. Users should be aware that fragment products may vary in their specific sequences and biological activity.

Published clinical data apply to full-length thymosin beta-4, not to the commercially sold fragment; the fragment has no dedicated human trials; dosing, stability and safety of 'TB-500' products are unregulated and poorly documented.

The 43-amino-acid thymosin beta-4 sequesters actin monomers (via the LKKTETQ actin-binding motif) and promotes cell migration, angiogenesis and wound healing. The fragment marketed as TB-500 contains the actin-binding domain. Pharmacokinetics of the fragment in humans are not published.